NovoCure Q2 Revenue Jumps 6 Percent

NovoCure (NASDAQ:NVCR), the oncology device firm advancing Tumor Treating Fields therapy, released its second quarter 2025 results on July 24, 2025. GAAP revenue totaled $158.8 million in Q2 2025, an increase of 6% year over year and surpassing the $154.16 million analyst consensus (GAAP). GAAP net loss per share was $0.36, also better than the estimated GAAP loss of $0.38. Operating losses and a decline in gross margin (GAAP) persisted due to the costs of new product launches and tariffs. The quarter showed strong patient growth and pipeline progress, but short-term profitability remains a challenge as NovoCure invests for the future. Source: Analyst estimates for the quarter provided by FactSet. NovoCure is an oncology technology company that develops and markets Tumor Treating Fields (TTFields) therapy—an electrical field-based device treatment for solid tumor cancers. Its primary products, Optune Gio and Optune Lua, are wearable medical devices designed for continuous use by patients to slow or stop cancer cell division.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool